Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of
OR-MTX chemotherapy（Orelabrutinib, Rituximab and Methotrexate）as first-line regimens in the
treatment of newly diagnosed primary central nervous system lymphoma. Objective response rate
is the primary endpoint.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University